Buscar
Mostrando ítems 31-40 de 144
Treatment With Dasatinib Or Nilotinib In Chronic Myeloid Leukemia Patients Who Failed To Respond To Two Previously Administered Tyrosine Kinase - Inhibitors A Single Center Experience
(HOSPITAL CLINICAS, UNIV SAO PAULOSAO PAULO, 2015)
Is p190 bcr-abl rearrangement necessary for acute transformation in some p210 CML of childhood?
(PERGAMON-ELSEVIER SCIENCE LTD, 2009)
Chronic myeloid leukemia (CML) is a rare disease in childhood which is almost exclusively associated with bcr-abl p210 (M-bcr) rearrangements. It has been suggested that co-expression of p 190 and p210 may be a pathway of ...
Frequency of the BCR/ABL rearrangements and associated alterations detected by FISH during monitoring of patients taking imatinib mesylate in isolation
(Associação Brasileira de Hematologia e Hemoterapia e daSociedade Brasileira de Transplante de Medula Óssea, 2014)
Monitoring of BCR-ABL levels in chronic myeloid leukemia patients treated with imatinib in the chronic phase: the importance of a major molecular response
(Associação Brasileira de Hematologia e Hemoterapia e daSociedade Brasileira de Transplante de Medula Óssea, 2011)
BACKGROUND: Real time PCR has become the most common technique to monitor BCR-ABL transcript levels of patients treated with kinase inhibitors. The aim of this study was to evaluate BCR-ABL levels of chronic myeloid leukemia ...
Analysis of imatinib adherence in chronic myeloid leukemia: a retrospective study in a referral hospital in the brazilian amazonAnálise da adesão ao imatinibe na leucemia mielóide crônica: estudo retrospectivo em hospital de referência na amazônia brasileira
(Associação Brasileira de Hematologia, Hemoterapia e Terapia CelularBrasilABHH, 2019)